Mylan, a Viatris company, has sold its entire 5.64% stake in Biocon through block deals at ₹400 per share. The transaction attracted significant interest from 36 institutional investors, with major mutual funds leading the buying. The stock rose 6.4% on the National Stock Exchange following the completion of this exit.
Mylan has officially ended its long-standing investment in Biocon by selling its entire 5.64% stake in the company. The shares were offloaded in a series of block deals on July 13, totaling approximately ₹3,678.68 crore. The transaction involved the sale of 4.59 crore shares at a fixed price of ₹400 each.
Following the news of the exit, Biocon shares experienced a positive market reaction, climbing 6.4% to reach ₹437.3 on the National Stock Exchange. The stock saw high trading activity as investors digested the news of the promoter-related entity's departure and the subsequent entry of new institutional shareholders.
Strong Institutional Demand for Biocon
The divestment process saw robust participation from both domestic and global financial institutions, with a total of 36 investors acquiring the shares offloaded by Mylan. ICICI Prudential Mutual Fund emerged as the largest buyer, securing a 2.26% stake in the company for roughly ₹1,475 crore. Other notable domestic mutual funds, including Kotak Mahindra Mutual Fund and HDFC Mutual Fund, also took significant positions, each acquiring 0.71% of the equity.
This broad participation reflects continued institutional interest in the company's business model. Other notable participants included large asset management firms and insurers such as SBI Mutual Fund, Axis Mutual Fund, Motilal Oswal AMC, and HDFC Life Insurance. International investment houses, including Goldman Sachs, Morgan Stanley, and Citigroup, also took part in the transaction, signaling that the sale was well-absorbed by the market without a long-term overhang.
Strategic Context and Investor Monitorables
For Biocon, the departure of Mylan—a key partner in its biosimilars business—marks a shift in its shareholder structure. While this exit eliminates the risk of further large-scale selling by Mylan, investors may monitor how the company manages its strategic partnerships and capital allocation moving forward. Historically, Biocon has been focused on expanding its global biosimilars footprint and managing the debt associated with its complex research and manufacturing operations.
The primary monitorable for shareholders will be the company’s ability to maintain its profit margins and sustain growth in its core biopharmaceutical segments. Investors may watch upcoming quarterly results to assess whether the company's operational performance remains aligned with the expectations of these new institutional shareholders, particularly as it navigates competitive pricing in the global biosimilars sector.